By 2010, such purchases were predominantly generic drugs . For example, by 2008, 95% (by volume) of the global donor-funded ARV market was comprised of generics, primarily from India. The generic proportion of PEPFAR-purchased ARVs grew from 15% to 89% from 2005 to 2008, with estimated savings to PEPFAR totalling $323 million over the four-year period .
Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
Ellen ‘t Hoen, Jonathan Berger, Alexandra Calmy, and Suerie Moon